Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial.
Major cardiovascular events
Metabolic dysfunction-associated fatty liver disease (MAFLD)
Prevention
Randomized open-labeled trial
Journal
Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
30
01
2023
accepted:
18
04
2023
medline:
31
7
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
ppublish
Résumé
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a novel term that distinguishes patients at risk of adverse clinical outcomes with higher accuracy than those with non-alcoholic fatty liver disease (NAFLD). Cardiovascular mortality is the leading cause of death in MAFLD. The current literature lacks large-scale prospective studies that address preventive approaches for cardiovascular health in MAFLD. We investigated whether MAFLD patients benefit from a fixed-dose combination therapy (Aspirin, hydrochlorothiazide, atorvastatin, valsartan), known as a Polypill. Analysis was performed (stratified based on MAFLD status) of a clinical trial that included 1596 individuals randomly allocated to an intervention (polypill) or a control (usual care) group. Patients were followed up for five years for any adverse drug reaction, major cardiovascular events, and mortality. Univariable and multivariable survival analyses were performed, and the interaction level was assessed by R programming. Patients who consumed the polypill had significantly lower hazard ratios of major cardiovascular events incidence (HR 0.56, 95% CI 0.41-0.78) and cardiovascular mortality (HR 0.41, 95% CI 0.2-0.86) compared to the control group. Polypill showed significantly better results in lowering cardiovascular events in MAFLD patients than in the general population. (p-value for interaction: 0.028). Moreover, comparing those patients who had high adherence to the Polypill, with the control group, further enhanced the results. Major cardiovascular events are prevented in MAFLD patients who consume the Polypill. MAFLD patients benefit from the Polypill more than the general population.
Sections du résumé
BACKGROUND
BACKGROUND
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a novel term that distinguishes patients at risk of adverse clinical outcomes with higher accuracy than those with non-alcoholic fatty liver disease (NAFLD). Cardiovascular mortality is the leading cause of death in MAFLD. The current literature lacks large-scale prospective studies that address preventive approaches for cardiovascular health in MAFLD. We investigated whether MAFLD patients benefit from a fixed-dose combination therapy (Aspirin, hydrochlorothiazide, atorvastatin, valsartan), known as a Polypill.
METHODS
METHODS
Analysis was performed (stratified based on MAFLD status) of a clinical trial that included 1596 individuals randomly allocated to an intervention (polypill) or a control (usual care) group. Patients were followed up for five years for any adverse drug reaction, major cardiovascular events, and mortality. Univariable and multivariable survival analyses were performed, and the interaction level was assessed by R programming.
RESULTS
RESULTS
Patients who consumed the polypill had significantly lower hazard ratios of major cardiovascular events incidence (HR 0.56, 95% CI 0.41-0.78) and cardiovascular mortality (HR 0.41, 95% CI 0.2-0.86) compared to the control group. Polypill showed significantly better results in lowering cardiovascular events in MAFLD patients than in the general population. (p-value for interaction: 0.028). Moreover, comparing those patients who had high adherence to the Polypill, with the control group, further enhanced the results.
CONCLUSIONS
CONCLUSIONS
Major cardiovascular events are prevented in MAFLD patients who consume the Polypill. MAFLD patients benefit from the Polypill more than the general population.
Identifiants
pubmed: 37227560
doi: 10.1007/s12072-023-10542-9
pii: 10.1007/s12072-023-10542-9
doi:
Substances chimiques
Aspirin
R16CO5Y76E
Drug Combinations
0
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
882-888Informations de copyright
© 2023. Asian Pacific Association for the Study of the Liver.
Références
Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1
doi: 10.1053/j.gastro.2019.11.312
pubmed: 32044314
Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front Med (Lausanne). 2021;8: 693507
doi: 10.3389/fmed.2021.693507
pubmed: 34277667
Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int. 2020;40(9):2082–2089
doi: 10.1111/liv.14548
pubmed: 32478487
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10
doi: 10.1053/j.gastro.2015.04.043
pubmed: 25935633
Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009;44(10):1236–1243
doi: 10.1080/00365520903171284
pubmed: 19670076
Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865–873
doi: 10.1002/hep.21327
pubmed: 17006923
Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209
doi: 10.1016/j.jhep.2020.03.039
pubmed: 32278004
Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–238
doi: 10.1016/j.cgh.2008.11.005
pubmed: 19049831
Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51(2):595–602
doi: 10.1002/hep.23314
pubmed: 20014114
Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005;54(12):3541–3546
doi: 10.2337/diabetes.54.12.3541
pubmed: 16306373
Merat S, Jafari E, Radmard AR, Khoshnia M, Sharafkhah M, Nateghi Baygi A, et al. Polypill for prevention of cardiovascular diseases with focus on non-alcoholic steatohepatitis: the PolyIran-Liver trial. Eur Heart J. 2022;43(21):2023–2033
doi: 10.1093/eurheartj/ehab919
pubmed: 35048107
de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;4(4):Cd009868
pubmed: 24737108
Kandil OA, Motawea KR, Aboelenein MM, Shah J. Polypills for primary prevention of cardiovascular disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9: 880054
doi: 10.3389/fcvm.2022.880054
pubmed: 35498049
pmcid: 9046936
Merat S, Poustchi H, Hemming K, Jafari E, Radmard AR, Nateghi A, et al. PolyPill for prevention of cardiovascular disease in an Urban Iranian population with special focus on nonalcoholic steatohepatitis: A pragmatic randomized controlled trial within a cohort (PolyIran—liver)—study protocol. Arch Iran Med. 2015;18(8):515–523
pubmed: 26265520
Nansseu JR, Tankeu AT, Kamtchum-Tatuene J, Noubiap JJ. Fixed-dose combination therapy to reduce the growing burden of cardiovascular disease in low- and middle-income countries: feasibility and challenges. J Clin Hypertens (Greenwich). 2018;20(1):168–173
doi: 10.1111/jch.13162
pubmed: 29316126
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019;394(10199):672–683
doi: 10.1016/S0140-6736(19)31791-X
pubmed: 31448738
Roy A, Naik N, Srinath RK. Strengths and limitations of using the polypill in cardiovascular prevention. Curr Cardiol Rep. 2017;19(5):45
doi: 10.1007/s11886-017-0853-y
pubmed: 28425033
pmcid: 5397453
Pourshams A, Khademi H, Malekshah AF, Islami F, Nouraei M, Sadjadi AR, et al. Cohort profile: the Golestan cohort study–a prospective study of oesophageal cancer in northern Iran. Int J Epidemiol. 2010;39(1):52–59
doi: 10.1093/ije/dyp161
pubmed: 19332502
Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, et al. MAFLD Predicts the risk of cardiovascular disease better than NAFLD in asymptomatic subjects with health check-ups. Dig Dis Sci. 2022;67(10):4919–4928
doi: 10.1007/s10620-022-07508-6
pubmed: 35579799
Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138–47.e10
doi: 10.1016/j.cgh.2020.12.022
pubmed: 33348045
Liu HH, Cao YX, Jin JL, Guo YL, Zhu CG, Wu NQ, et al. Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case-control study. Hepatol Int. 2021;15(6):1337–1346
doi: 10.1007/s12072-021-10252-0
pubmed: 34626331
Liu S, Wang J, Wu S, Niu J, Zheng R, Bie L, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021;120: 154779
doi: 10.1016/j.metabol.2021.154779
pubmed: 33895182
Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, et al. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the Suita study. J Atheroscler Thromb. 2016;23(9):1138–1139
doi: 10.5551/jat.Er19356
pubmed: 27582077
Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128
doi: 10.1111/hepr.13685
pubmed: 34129272
Zhang HJ, Wang YY, Chen C, Lu YL, Wang NJ. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999–2016. Chin Med J (Engl). 2021;134(13):1593–1601
doi: 10.1097/CM9.0000000000001513
pubmed: 34091530
Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, et al. An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One. 2011;6(5): e19857
pubmed: 21647425
Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7(7): e41297
doi: 10.1371/journal.pone.0041297
pubmed: 22815989
pmcid: 3399742
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326(7404):1419
doi: 10.1136/bmj.326.7404.1419
pubmed: 12829553
pmcid: 162259
Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54–65
doi: 10.3121/cmr.2013.1113
pubmed: 23580788
pmcid: 3692389